Anti-angiogenic agents have played crucial roles in the treatment of ovarian 
cancer in recent years, but potential benefits of endostatin have been largely 
unexplored. The present retrospective study evaluated its efficacy and toxicity 
with two cohorts of patients with platinum-resistant recurrent ovarian cancer. 
One cohort received gemcitabine plus endostar (rh-endostatin), and the second 
cohort received gemcitabine regimen alone, with totals of 31 and 27 patients, 
respectively. The main endpoints were disease control rate (DCR), PFS, overall 
survival (OS) and safety. There were statistically significant differences in 
DCR (70.9% vs. 40.7%; P = 0.02) and PFS (6.3 months vs. 3.2 months, P = 0.001) 
between the two cohorts. Though the endostar cohort also improved median OS by 
2.1 months, there was no statistically significant difference compared with 
gemcitabine alone cohort in this case (12.5 months vs. 10.4 months, P = 0.201). 
Treatment was well tolerated for most patients, and toxicity of endostar was 
negligible. Gemcitabine plus endostar significantly improved the prognosis in 
patients with platinum-resistant recurrent ovarian cancer, especially in those 
with malignant effusion. The endostar- containing regimen is recommended in this 
setting.